Table 3 Treatment-emergent adverse events during Dara-KRd.
Adverse event | All grades, n (%) (n = 42) | Grade 3+, n (%) (n = 42) |
|---|---|---|
Hematologic | ||
Lymphopenia | 29 (69%) | 15 (36%) |
Thrombocytopenia | 27 (64%) | 11 (26%) |
Anemia | 25 (59%) | 1 (2%) |
Neutropenia | 11 (26%) | 9 (21%) |
Non-hematologic | ||
Fatigue | 37 (88%) | 1 (2%) |
Infection | ||
Upper respiratorya | 28 (67%) | 3 (7%) |
Skin/Soft Tissue | 5 (12%) | 1 (2%) |
Urinary tract | 2 (5%) | 0 (0%) |
Otherb | 9 (21%) | 0 (0%) |
Hyperglycemia | 32 (76%) | 3 (7%) |
Diarrhea | 30 (71%) | 2 (5%) |
Lower extremity edema | 28 (67%) | 0 (0%) |
Dyspnea | 26 (62%) | 0 (0%) |
Hypertension | 24 (57%) | 7 (17%) |
Liver enzyme elevations | 17 (40%) | 4 (10%) |
Peripheral sensory neuropathy | 17 (40%) | 0 (0%) |
Nausea | 15 (35%) | 1 (2%) |
Cardiac events, any | ||
Chest pain | 3 (7%) | 0 (0%) |
Atrial fibrillation | 2 (5%) | 1 (2%) |
Sinus bradycardia | 4 (10%) | 0 (0%) |
Sinus tachycardia | 3 (7%) | 0 (0%) |
Reduced ejection fraction | 4 (10%) | 1 (2%) |
Electrolyte imbalances, any | ||
Hyperkalemia | 5 (12%) | 1 (2%) |
Hypocalcemia | 13 (31%) | 2 (5%) |
Hypokalemia | 23 (55%) | 4 (10%) |
Hypomagnesemia | 5 (12%) | 0 (0%) |
Hypophosphatemia | 9 (21%) | 1 (2%) |
Hyponatremia | 4 (10%) | 0 (0%) |
Rash | 13 (31%) | 2 (5%) |
Blurred vision | 11 (26%) | 0 (0%) |
Acute kidney injuryc | 8 (19%) | 2 (5%) |
Infusion reactions | 4 (10%) | 0 (0%) |
